Atezolizumab time-varying population PK
A two-compartment population PK model representing atezolizumab disposition, clinical covariate effects, time-varying clearance, concentration, and interval exposure.
- Therapeutic
- Atezolizumab
- Target
- PD-L1 / CD274
- Disease
- Oncology dosing-regimen simulation
Biological model
A two-compartment population PK model representing atezolizumab disposition, clinical covariate effects, time-varying clearance, concentration, and interval exposure.
Intervention
Atezolizumab
Biological focus
PD-L1 / CD274
Context
Oncology dosing-regimen simulation
Model details
A two-compartment population PK model representing atezolizumab disposition, clinical covariate effects, time-varying clearance, concentration, and interval exposure.
Modeled states
- auc ug day mlug*day/mL
Modeled dynamic state for auc ug day ml.
- central mgmg
Modeled dynamic state for central mg.
- elapsed dayday
Modeled dynamic state for elapsed day.
- peripheral mgmg
Modeled dynamic state for peripheral mg.
Key readouts
- Atezolizumab concentrationunknown
Model-derived readout for atezolizumab concentration.
- Cumulative atezolizumab exposureug*day/mL
Model-derived readout for cumulative atezolizumab exposure.
- Time-varying clearanceunknown
Model-derived readout for time-varying clearance.
- Current weekly exposureunknown
Model-derived readout for current weekly exposure.
- central mgmg
Model-derived readout for central mg.
Explore this model
Choose a starting point to view its result. Adjust key model inputs when you want to explore a different outcome.
1200 mg every 3 weeks standard dosing
How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure? Explore this intervention regimen through Atezolizumab concentration, Cumulative atezolizumab exposure, Time-varying clearance, Current weekly exposure. This is a mechanistic product exploration, not a paper-result reproduction.
Questions to explore
- How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure?
Starting result
This result reflects the starting settings. Run your changes to update it.
Model inputs
Five scientist-facing controls at most.
Compare a parameter
How does one model input change the response?
How do dosing interval and time-varying clearance change atezolizumab concentration and weekly exposure?
theta cl l day
Model parameter controlling theta cl l day.
Exploratory range around the default value.
5 evenly spaced values in L/day. Other model inputs and the simulation window stay fixed.
Interpret with care
- Interpret trajectories as deterministic model behavior, not as a patient-specific prediction or dosing recommendation.
- Paper-result and exact-anchor checks remain in the private validation lane and are not part of this public scenario.
Review the server-confirmed fixed price before starting the comparison.
Comparative response
End-of-window response across the selected parameter values.
Choose an exploratory range around the default, review the fixed price, and run the comparison.
Scientific reference
Supporting publication
A comparison of pharmacometric software programs for atezolizumab population pharmacokinetic simulationEuropean Journal of Clinical Pharmacology
